Clinical Trials Logo

Clinical Trial Summary

It is aimed to compare the ocular findings in patients with natural and surgical menopause.


Clinical Trial Description

To compare the parameters such as fundus examination, macular thickness, visual acuity and lens opacities among female patients diagnosed with menopause between the ages of 40-65.The criteria for exclusion from the study are the presence of a history of illness, drug use, smoking and alcohol use.Inclusion criteria were female patients who were in menopause and who did not use any medications. For surgical menopause, the uterus and ovaries were surgically removed at least 3 months ago. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04703231
Study type Observational
Source Batman Maternity and Child's Health Hospital
Contact
Status Completed
Phase
Start date September 1, 2020
Completion date March 23, 2022

See also
  Status Clinical Trial Phase
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Recruiting NCT04775849 - Intraoperative Berger Space Imaging (IBSI) N/A
Active, not recruiting NCT04120636 - Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Not yet recruiting NCT04977427 - Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes Phase 4
Recruiting NCT05122702 - An Innovative Chinese Herbal Formula for Macular Edema Phase 2
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Completed NCT04359771 - Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema Phase 4
Completed NCT05385562 - Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions N/A
Recruiting NCT04847869 - Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema N/A
Completed NCT03093701 - TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 2